Humoral Immunity Elicited by the XBB.1.5 Monovalent COVID-19 Vaccine
preprint
OA: closed
AI-generated summary
The XBB.1.5 monovalent COVID-19 vaccine boosted IgG, IgA, and total IgG/A/M antibodies against the spike receptor-binding domain and increased neutralizing titers against multiple SARS-CoV-2 variants.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
As novel SARS-CoV-2 variants continue to emerge, the updated XBB.1.5 monovalent vaccines remain to be evaluated in terms of immunogenicity against live clinical isolates. We report boosting of IgG(2.1X), IgA(1.5X), and total IgG/A/M(1.7X) antibodies targeting the spike receptor-binding domain and neutralizing titers against WA1(2.2X), XBB.1.5(7.4X), EG.5.1(10.5X), and JN.1(4.7X) variants.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
Source provenance
- europepmc
- last seen: 2026-05-20T01:45:00.602351+00:00